| 668 | Humans |
| 390 | Female |
| 321 | Male |
| 246 | Middle Aged |
| 200 | Adult |
| 192 | Aged |
| 105 | Treatment Outcome |
| 98 | Adolescent |
| 94 | Animals |
| 90 | Polymorphism, Single Nucleotide |
| 89 | Genetic Predisposition to Disease |
| 85 | Young Adult |
| 79 | Risk Factors |
| 72 | Genome-Wide Association Study |
| 69 | Child |
| 64 | Aged, 80 and over |
| 60 | Breast Neoplasms |
| 59 | Case-Control Studies |
| 52 | Genotype |
| 51 | Prognosis |
| 49 | Time Factors |
| 43 | Mutation |
| 43 | Child, Preschool |
| 38 | Double-Blind Method |
| 37 | Practice Guidelines as Topic |
| 35 | Infant |
| 34 | Follow-Up Studies |
| 34 | Europe |
| 34 | Disease-Free Survival |
| 34 | Age Factors |
| 33 | Antineoplastic Combined Chemotherapy Protocols |
| 32 | Retrospective Studies |
| 32 | Phenotype |
| 32 | Cohort Studies |
| 31 | Global Health |
| 31 | European Continental Ancestry Group |
| 29 | Risk |
| 29 | Prospective Studies |
| 28 | Survival Rate |
| 28 | Ovarian Neoplasms |
| 28 | Genetic Variation |
| 27 | Severity of Illness Index |
| 27 | Neoplasms |
| 26 | Neoplasm Staging |
| 25 | Risk Assessment |
| 25 | Evidence-Based Medicine |
| 24 | Reproducibility of Results |
| 24 | Mice |
| 24 | International Cooperation |
| 24 | Disease Progression |
| 24 | Antineoplastic Agents |
| 22 | Surveys and Questionnaires |
| 22 | Proportional Hazards Models |
| 22 | Odds Ratio |
| 22 | Genetic Association Studies |
| 21 | Genetic Loci |
| 21 | Drug Therapy, Combination |
| 21 | Consensus |
| 21 | Alleles |
| 20 | Signal Transduction |
| 20 | Quality of Life |
| 20 | Kaplan-Meier Estimate |
| 20 | Clinical Trials as Topic |
| 19 | Registries |
| 19 | Randomized Controlled Trials as Topic |
| 19 | Quantitative Trait Loci |
| 19 | Magnetic Resonance Imaging |
| 19 | Incidence |
| 19 | Chromosome Mapping |
| 18 | Phylogeny |
| 18 | Internationality |
| 18 | Brain |
| 17 | Sequence Analysis, DNA |
| 17 | Recurrence |
| 17 | Neoplasm Recurrence, Local |
| 17 | Infant, Newborn |
| 17 | Genome, Human |
| 17 | Drug Administration Schedule |
| 17 | Computational Biology |
| 16 | Research Design |
| 16 | Biodiversity |
| 16 | Australia |
| 15 | Societies, Medical |
| 15 | Molecular Sequence Data |
| 15 | Genomics |
| 15 | Disease Management |
| 15 | Body Mass Index |
| 14 | Stroke |
| 14 | High-Throughput Nucleotide Sequencing |
| 14 | Cross-Sectional Studies |
| 14 | Algorithms |
| 13 | Survival Analysis |
| 13 | Prostatic Neoplasms |
| 13 | Melanoma |
| 13 | Hematopoietic Stem Cell Transplantation |
| 13 | Guidelines as Topic |
| 13 | Gene Expression Profiling |
| 13 | Exome |
| 13 | Evolution, Molecular |
| 13 | Canada |
| 13 | Antibodies, Monoclonal, Humanized |
| 12 | Prevalence |
| 12 | Outcome Assessment (Health Care) |
| 12 | Mutation, Missense |
| 12 | Multivariate Analysis |
| 12 | Imidazoles |
| 12 | Gene Frequency |
| 12 | Ecosystem |
| 12 | Conservation of Natural Resources |
| 12 | Antiviral Agents |
| 12 | Antibodies, Monoclonal |
| 12 | Age of Onset |
| 11 | Tumor Suppressor Proteins |
| 11 | Software |
| 11 | Sex Factors |
| 11 | Pregnancy |
| 11 | Neuropsychological Tests |
| 11 | Neoplasm Grading |
| 11 | Hospital Mortality |
| 11 | Haplotypes |
| 11 | Genetic Testing |
| 11 | Databases, Genetic |
| 11 | Databases, Factual |
| 11 | DNA Mutational Analysis |
| 11 | Biomarkers |
| 10 | Skin Neoplasms |
| 10 | Promoter Regions, Genetic |
| 10 | Pedigree |
| 10 | Meta-Analysis as Topic |
| 10 | Lung Neoplasms |
| 10 | Heterozygote |
| 10 | Germ-Line Mutation |
| 10 | Dose-Response Relationship, Drug |
| 10 | Cognition Disorders |
| 10 | BRCA1 Protein |
| 10 | Amino Acid Sequence |
| 10 | Aging |
| 9 | Viral Load |
| 9 | United States |
| 9 | Species Specificity |
| 9 | Respiration, Artificial |
| 9 | Remission Induction |
| 9 | Recombinant Proteins |
| 9 | Protein Kinase Inhibitors |
| 9 | Polyethylene Glycols |
| 9 | Paclitaxel |
| 9 | Myocardial Infarction |
| 9 | Logistic Models |
| 9 | Injections, Subcutaneous |
| 9 | Immunosuppressive Agents |
| 9 | Hospitalization |
| 9 | Electrocardiography |
| 9 | Diabetes Mellitus, Type 2 |
| 9 | Colorectal Neoplasms |
| 9 | Cell Line, Tumor |
| 9 | Cardiovascular Diseases |
| 9 | Brain Neoplasms |
| 9 | Brain Ischemia |
| 9 | Bipolar Disorder |
| 9 | Biomarkers, Tumor |
| 9 | Adenocarcinoma |
| 8 | Transplantation Conditioning |
| 8 | Terminology as Topic |
| 8 | Respiratory Distress Syndrome, Adult |
| 8 | Receptor, ErbB-2 |
| 8 | Predictive Value of Tests |
| 8 | Percutaneous Coronary Intervention |
| 8 | Obesity |
| 8 | Nuclear Proteins |
| 8 | Models, Biological |
| 8 | Membrane Proteins |
| 8 | Longitudinal Studies |
| 8 | Kidney Neoplasms |
| 8 | Information Dissemination |
| 8 | Hepatitis C, Chronic |
| 8 | Genes, BRCA2 |
| 8 | Gene Expression Regulation |
| 8 | Disease Models, Animal |
| 8 | DNA-Binding Proteins |
| 8 | DNA Copy Number Variations |
| 8 | Combined Modality Therapy |
| 8 | Carrier Proteins |
| 8 | Blood Pressure |
| 8 | Biological Evolution |
| 8 | Base Sequence |
| 8 | Asthma |
| 8 | Arthritis, Rheumatoid |
| 7 | United Kingdom |
| 7 | Smoking |
| 7 | Sex Distribution |
| 7 | Sensitivity and Specificity |
| 7 | Rheumatology |
| 7 | Receptors, Estrogen |
| 7 | RNA, Messenger |
| 7 | Pyrimidines |
| 7 | Nerve Tissue Proteins |
| 7 | Neoplasm Metastasis |
| 7 | Multiple Myeloma |
| 7 | Models, Statistical |
| 7 | Mice, Inbred C57BL |
| 7 | Intensive Care Units |
| 7 | Immunohistochemistry |
| 7 | HIV Infections |
| 7 | Glioma |
| 7 | Genes, BRCA1 |
| 7 | Gene Expression Regulation, Neoplastic |
| 7 | Extinction, Biological |
| 7 | Comorbidity |
| 7 | Cause of Death |
| 7 | Carcinoma, Renal Cell |
| 7 | Bone Neoplasms |
| 7 | Blood Glucose |
| 7 | Biomedical Research |
| 7 | Asian Continental Ancestry Group |
| 7 | Alzheimer Disease |
| 7 | Age Distribution |
| 7 | Acute Coronary Syndrome |
| 6 | Trees |
| 6 | Transplantation, Homologous |
| 6 | Transcription Factors |
| 6 | Rituximab |
| 6 | Ribavirin |
| 6 | Reproduction |
| 6 | Protein Conformation |
| 6 | Prostatic Neoplasms, Castration-Resistant |
| 6 | Plants |
| 6 | Neoplasms, Glandular and Epithelial |
| 6 | Neoplasm Invasiveness |
| 6 | Mortality |
| 6 | Models, Molecular |
| 6 | Models, Genetic |
| 6 | Mendelian Randomization Analysis |
| 6 | MCF-7 Cells |
| 6 | International Agencies |
| 6 | Image Processing, Computer-Assisted |
| 6 | Hypertension |
| 6 | Huntington Disease |
| 6 | Hepacivirus |
| 6 | Geography |
| 6 | Genome, Plant |
| 6 | Genetic Markers |
| 6 | France |
| 6 | Forced Expiratory Volume |
| 6 | Epilepsy |
| 6 | Environment |
| 6 | Enhancer Elements, Genetic |
| 6 | Dementia |
| 6 | Cyclophosphamide |
| 6 | Cooperative Behavior |
| 6 | Colitis, Ulcerative |
| 6 | Cognition |
| 6 | Climate Change |
| 6 | Chemotherapy, Adjuvant |
| 6 | Bone Density Conservation Agents |
| 6 | Body Height |
| 6 | Bayes Theorem |
| 6 | BRCA2 Protein |
| 6 | Adrenal Cortex Hormones |
| 6 | Administration, Intravenous |
| 5 | World Health Organization |
| 5 | Uterine Cervical Neoplasms |
| 5 | Tuberculosis |
| 5 | Travel |
| 5 | Tissue Plasminogen Activator |
| 5 | Thrombectomy |
| 5 | Sulfonamides |
| 5 | Stents |
| 5 | Schizophrenia |
| 5 | Rheumatic Diseases |
| 5 | Regression Analysis |
| 5 | Quinazolines |
| 5 | Pulmonary Disease, Chronic Obstructive |
| 5 | Protein Binding |
| 5 | Prosthesis Design |
| 5 | Prednisone |
| 5 | Precision Medicine |
| 5 | Postoperative Complications |
| 5 | Population Surveillance |
| 5 | Patient Selection |
| 5 | Papillomavirus Infections |
| 5 | Pancreatic Neoplasms |
| 5 | Outcome and Process Assessment (Health Care) |
| 5 | Osteoarthritis, Knee |
| 5 | Oceans and Seas |
| 5 | Occupational Exposure |
| 5 | North America |
| 5 | Molecular Sequence Annotation |
| 5 | Mice, Knockout |
| 5 | Methotrexate |
| 5 | Mass Screening |
| 5 | Lupus Erythematosus, Systemic |
| 5 | Leukemia, Myeloid, Acute |
| 5 | Internet |
| 5 | Interferon-alpha |
| 5 | Infusions, Intravenous |
| 5 | Indoles |
| 5 | Hypoglycemic Agents |
| 5 | Hypertension, Pulmonary |
| 5 | Homozygote |
| 5 | Hepatitis B, Chronic |
| 5 | Heart Rate |
| 5 | Heart Failure |
| 5 | Health Services Accessibility |
| 5 | Health Knowledge, Attitudes, Practice |
| 5 | Graft vs Host Disease |
| 5 | Genotyping Techniques |
| 5 | Genome, Bacterial |
| 5 | Gene Dosage |
| 5 | Fishes |
| 5 | Exons |
| 5 | Exercise |
| 5 | Exercise Therapy |
| 5 | Epigenesis, Genetic |
| 5 | Endometrial Neoplasms |
| 5 | Educational Status |
| 5 | Early Detection of Cancer |
| 5 | Drug-Related Side Effects and Adverse Reactions |
| 5 | Drug Resistance, Neoplasm |
| 5 | Depressive Disorder, Major |
| 5 | Denosumab |
| 5 | Datasets as Topic |
| 5 | Dacarbazine |
| 5 | DNA, Viral |
| 5 | DNA Methylation |
| 5 | Coronary Artery Disease |
| 5 | Computer Simulation |
| 5 | Cluster Analysis |
| 5 | Climate |
| 5 | Cells, Cultured |
| 5 | Cell Cycle Proteins |
| 5 | Bacteria |
| 5 | Atrial Fibrillation |
| 5 | Anticholesteremic Agents |
| 5 | Administration, Oral |
| 5 | Acute Disease |
| 4 | Withholding Treatment |
| 4 | Vidarabine |
| 4 | Vaccination |
| 4 | Tumor Suppressor Protein p53 |
| 4 | Tumor Necrosis Factor-alpha |
| 4 | Triazoles |
| 4 | Transcriptome |
| 4 | Tidal Volume |
| 4 | Temperature |
| 4 | Telomere Homeostasis |
| 4 | Socioeconomic Factors |
| 4 | Sex Characteristics |
| 4 | Self Report |
| 4 | Salvage Therapy |
| 4 | Repressor Proteins |
| 4 | Renal Insufficiency, Chronic |
| 4 | Renal Dialysis |
| 4 | Reference Standards |
| 4 | Quality Control |
| 4 | Pyrroles |
| 4 | Psychometrics |
| 4 | Proteins |
| 4 | Prodromal Symptoms |
| 4 | Pregnancy Complications |
| 4 | Population Dynamics |
| 4 | Plant Leaves |
| 4 | Phylogeography |
| 4 | Peptides |
| 4 | Patient Outcome Assessment |
| 4 | Patient Care Planning |
| 4 | Papillomavirus Vaccines |
| 4 | Pain Management |
| 4 | Osteoarthritis |
| 4 | Organizational Objectives |
| 4 | Occupational Diseases |
| 4 | New Zealand |
| 4 | Myeloablative Agonists |
| 4 | MicroRNAs |
| 4 | Medulloblastoma |
| 4 | Medical Oncology |
| 4 | Malaria |
| 4 | Maintenance Chemotherapy |
| 4 | Lymphatic Metastasis |
| 4 | Linkage Disequilibrium |
| 4 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| 4 | Leukemia, Lymphocytic, Chronic, B-Cell |
| 4 | Islands |
| 4 | Insulin |
| 4 | Insulin Resistance |
| 4 | Inflammation |
| 4 | In Situ Hybridization, Fluorescence |
| 4 | Image Interpretation, Computer-Assisted |
| 4 | Hyperlipoproteinemia Type II |
| 4 | History, Ancient |
| 4 | Hepatitis B Surface Antigens |
| 4 | Heart Defects, Congenital |
| 4 | HLA Antigens |
| 4 | HEK293 Cells |
| 4 | Germany |
| 4 | Genome |
| 4 | Genome, Viral |
| 4 | Gene Expression |
| 4 | Forests |
| 4 | Forecasting |
| 4 | Fibrinolytic Agents |
| 4 | Feeding and Eating Disorders |
| 4 | Drug Combinations |
| 4 | Doxorubicin |
| 4 | Disease Outbreaks |
| 4 | Diagnosis, Differential |
| 4 | Dermatitis, Atopic |
| 4 | Delphi Technique |
| 4 | DNA |
| 4 | DNA Repair |
| 4 | Cystic Fibrosis |
| 4 | Crohn Disease |
| 4 | Critical Illness |
| 4 | Critical Care |
| 4 | Coronary Angiography |
| 4 | Coral Reefs |
| 4 | Congresses as Topic |
| 4 | Cognitive Dysfunction |
| 4 | Clinical Trials, Phase III as Topic |
| 4 | Clinical Decision-Making |
| 4 | Chromosomes, Human, Pair 5 |
| 4 | Chromosomes, Human, Pair 2 |
| 4 | Chromosome Aberrations |
| 4 | Chromatin |
| 4 | Checklist |
| 4 | Cell Line |
| 4 | Carcinogenesis |
| 4 | Carboplatin |
| 4 | Breast Density |
| 4 | Bone and Bones |
| 4 | Bone Marrow Transplantation |
| 4 | Blood Transfusion |
| 4 | Bevacizumab |
| 4 | Apoptosis |
| 4 | Antirheumatic Agents |
| 4 | Antineoplastic Agents, Hormonal |
| 4 | Antineoplastic Agents, Alkylating |
| 4 | Anti-Bacterial Agents |
| 4 | Analysis of Variance |
| 4 | Alanine Transaminase |
| 4 | Adiposity |
| 4 | Adaptor Proteins, Signal Transducing |
| 4 | Abnormalities, Multiple |
| 3 | Waste Water |
| 3 | Waist-Hip Ratio |
| 3 | Waist Circumference |
| 3 | Virulence |
| 3 | Tropical Climate |
| 3 | Translational Medical Research |
| 3 | Tomography, Optical Coherence |
| 3 | Thrombolytic Therapy |
| 3 | Tenofovir |
| 3 | Stroke Volume |
| 3 | Stomach Neoplasms |
| 3 | Statistics as Topic |
| 3 | Sports |
| 3 | Soil |
| 3 | Soil Pollutants |
| 3 | Sjogren's Syndrome |
| 3 | Siblings |
| 3 | Sequence Homology, Amino Acid |
| 3 | Sequence Alignment |
| 3 | Selection, Genetic |
| 3 | Secondary Prevention |
| 3 | Seasons |
| 3 | Scleroderma, Diffuse |
| 3 | Rhinitis, Allergic |
| 3 | Review Literature as Topic |
| 3 | Research |
| 3 | Recombinant Fusion Proteins |
| 3 | Receptors, Cell Surface |
| 3 | Rats |
| 3 | Rare Diseases |
| 3 | Radiotherapy |
| 3 | Radiotherapy, Adjuvant |
| 3 | ROC Curve |
| 3 | RNA, Viral |
| 3 | Quinolones |
| 3 | Quality of Health Care |
| 3 | Quality Indicators, Health Care |
| 3 | Quality Improvement |
| 3 | Pyridines |
| 3 | Pyrazoles |
| 3 | Public Health Surveillance |
| 3 | Puberty |
| 3 | Proto-Oncogene Proteins |
| 3 | Propensity Score |
| 3 | Predatory Behavior |
| 3 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| 3 | Positive-Pressure Respiration |
| 3 | Point Mutation |
| 3 | Plant Stems |
| 3 | Plant Proteins |
| 3 | Piperazines |
| 3 | Periodicals as Topic |
| 3 | Pediatrics |
| 3 | Patient-Centered Care |
| 3 | Patient Satisfaction |
| 3 | Patient Reported Outcome Measures |
| 3 | Patient Preference |
| 3 | Patient Participation |
